KINIKSA PHARMACEUTICALS LTD. 2023-2024 Proxy Voting Records

Description as filed by funds: Election of Class III Directors to serve until the 2027 Annual Meeting of Shareholders, and until their respective successors have been duly elected and qualified: Felix J Baker, Ph.D.

KINIKSA PHARMACEUTICALS LTD.’s own tally for this item (“Elect Director: Felix J. Baker, Ph.D.”): 31,885,339 for, 15,812,807 withheld, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 67% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 3,156,023 for, 6,701,599 withheld.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: Election of Class III Directors to serve until the 2027 Annual Meeting of Shareholders, and until their respective successors have been duly elected and qualified: Kimberly J. Popovits

KINIKSA PHARMACEUTICALS LTD.’s own tally for this item (“Elect Director: Kimberly J. Popovits”): 46,745,428 for, 952,718 withheld, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 9,408,878 for, 448,744 withheld.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: Election of Class III Directors to serve until the 2027 Annual Meeting of Shareholders, and until their respective successors have been duly elected and qualified: Tracey L. McCain

KINIKSA PHARMACEUTICALS LTD.’s own tally for this item (“Elect Director: Tracey L. McCain”): 46,746,052 for, 952,094 withheld, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 9,408,878 for, 448,744 withheld.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To approve the Scheme of Arrangement attached to the accompanying proxy statement as Annex A among the Company and its shareholders.

The 69 asset managers below reported 9,800,514 for, 39,223 against, 17,844 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

Description as filed by funds: To approve a motion to adjourn the Special Court-Ordered Meeting of the shareholders of the Company (the "Redomiciliation Meeting") to a later date to solicit additional proxies if there are insufficient proxies to approve the Scheme of Arrangement at the time of the Redomiciliation Meeting.

The 67 asset managers below reported 8,440,698 for, 1,316,292 against, 17,844 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2024 Annual Meeting pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.

KINIKSA PHARMACEUTICALS LTD.’s own tally for this item (“3. The approval, on a non - binding, advisory basis, of the compensation of our named executive officers as disclosed in the Company's proxy statement for the Annual Meeting pursuant to the applicable compensation disclo”): 46,903,551 for, 469,616 against — passed, per its Form 8-K filed June 5, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 was approved.”
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 68 managers: 9,807,770 for, 29,450 against, 17,844 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 137 managers: 23,446,115 for, 226,014 against, 26 not voted, 7 unknown. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: The appointment of PricewaterhouseCoopers LLP as the Company's auditor until the close of the Company's next Annual Meeting of Shareholders, the delegation to the Company's Board of Directors, through its Audit Committee, of the authority to set the auditor's remuneration for such period, and the ratification of the appointment of PricewaterhouseCoopers LLP, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

KINIKSA PHARMACEUTICALS LTD.’s own tally for this item (“2. The (a) appointment of PricewaterhouseCoopers LLP as the Company's auditor until the close of the Company's next Annual Meeting of Shareholders, (b) delegation to the Company's Board of Directors, through the Audit Co”): 50,512,245 for, 217,508 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 69 asset managers below reported 9,765,247 for, 74,490 against, 17,844 abstained.

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.